It is postulated that through these mechanisms, NAD+ repletion might improve cellular energy capacity and resistance to oxidative stress
Mimicking the extracellular world: from natural to fully synthetic matrices utilizing supramolecular biomaterials
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
They are involved in reactive oxygen species (such as superoxide anions, hydrogen peroxide, and hydroxyl radicals) and lipid peroxidation product (such as malondialdehyde, 4-hydroxynonenal, F2-isoprostane, leukotriene) detoxification generated during mitochondrial respiration
One regulatory note worth holding alongside his framing: the FDA placed several of the peptides he discusses (including BPC-157, CJC-1295, and Ipamorelin) onto a Category 2 list in 2023, citing a lack of safety data rather than reported harms
